

1502
Kishore

15C

DECEIVE
1-14-98**McGREGOR & ADLER**
A PROFESSIONAL CORPORATIONP.O. BOX 710509
HOUSTON, TEXAS 77271-0509

WRITER'S DIRECT DIAL

(713)-777-2321

WRITER'S DIRECT FACS.

(713)-777-6908

E. MAIL: BAADLER@i-link.net

INTELLECTUAL PROPERTY LAW
(PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW)

January 14, 1998

FACSIMILE COVER SHEETPLEASE DELIVER TO: Examiner G.S. Kishore, Ph.D.COMPANY: USPTO-Group 1502FACSIMILE NUMBER: (703) 305-5408NUMBER OF PAGES (COUNTING COVER SHEET): 7FROM: Dr. Benjamin AdlerMESSAGE: Please deliver to Examiner Kishore. Thanks. Dr. Adler

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of this transmittal, the information contained in this facsimile is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader is not the intended recipient or an employee or agent responsible for delivery, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please immediately notify Dr. Benjamin Adler at (713) 777-2321 and promptly return the facsimile. Thank you.

*8/ Reg for
Recons*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:	ART UNIT: 1502
T. STEINEMANN ET AL.	§
FILED: May 4, 1994	§
SERIAL NO.: 08/580,384	§
FOR: NOVEL OPHTHALMOLOGIC USES OF PROTEIN C	§
	DOCKET: D5715D

*Rec'd
1-21-98
DECEMBER
1-14-98*

Assistant Commissioner of Patents
BOX NON-FEE
Washington, D.C. 20231

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this Response is being transmitted via facsimile to the Patent Office on January 14, 1998.

Benjamin Aaron Adler
Benjamin Aaron Adler, Ph.D., J.D.

RESPONSE

Dear Sir:

Responsive to the Final Office Action mailed October 14, 1997, please enter the following amendments.

REMARKS

Applicant submits the following remarks. Reconsideration of this application in view of the remarks is respectfully requested.

The 35 USC §103 Rejections

Claims 22-27 stand rejected under 35 USC §103(a) as being unpatentable over **Galin** et al. or **Iverson** et al. in combination with **Bang** et al. and **Esmon** et al. Claims 28-29 stand rejected under 35 USC §103(a) as being unpatentable over **Galin** et al. or **Iverson** et al. in combination